Molecular mousetraps and the serpinopathies
- 1 April 2005
- journal article
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 33 (2) , 321-330
- https://doi.org/10.1042/bst0330321
Abstract
Members of the serine proteinase inhibitor or serpin superfamily inhibit their target proteinases by a remarkable conformational transition that involves the enzyme being translocated more than 70 Å (1 Å=10−10 m) from the upper to the lower pole of the inhibitor. This elegant mechanism is subverted by point mutations to form ordered polymers that are retained within the endoplasmic reticulum of secretory cells. The accumulation of polymers underlies the retention of mutants of α1-antitrypsin and neuroserpin within hepatocytes and neurons to cause cirrhosis and dementia respectively. The formation of polymers results in the failure to secrete mutants of other members of the serpin superfamily: antithrombin, C1 inhibitor and α1-antichymotrypsin, to cause a plasma deficiency that results in the clinical syndromes of thrombosis, angio-oedema and emphysema respectively. Understanding the common mechanism underlying the retention and deficiency of mutants of the serpins has allowed us to group these conditions as the serpinopathies. We review in this paper the molecular and structural basis of the serpinopathies and show how this has allowed the development of specific agents to block the polymerization that underlies disease.Keywords
This publication has 78 references indexed in Scilit:
- How Small Peptides Block and Reverse Serpin PolymerisationJournal of Molecular Biology, 2004
- A 2.1 Å resolution structure of an uncleaved α1-antitrypsin shows variability of the reactive center and other loops11Edited by R. HuberJournal of Molecular Biology, 2001
- Familial Encephalopathy with Neuroserpin Inclusion BodiesThe American Journal of Pathology, 1999
- A 2.6 å structure of a serpin polymer and implications for conformational diseaseJournal of Molecular Biology, 1999
- A Kinetic Mechanism for the Polymerization of α1-AntitrypsinPublished by Elsevier ,1999
- Implications for function and therapy of a 2.9 å structure of binary-complexed antithrombinJournal of Molecular Biology, 1998
- Wild-type α1-antitrypsin is in the canonical inhibitory conformationJournal of Molecular Biology, 1998
- Receptor‐mediated endocytosis of plasminogen activators and activator/inhibitor complexesFEBS Letters, 1994
- Comparative properties of human α‐1‐proteinase inhibitor glycosylation variantsFEBS Letters, 1990
- Replacement Therapy for Alpha1-Antitrypsin Deficiency Associated with EmphysemaNew England Journal of Medicine, 1987